Cure Today9h
Understanding the Benefit of Subcutaneous Versus IV Opdivo in Patients With Solid Tumors
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
The American Journal of Managed Care11h
Subcutaneous Ocrelizumab Well Tolerated in Patients With MS
Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
The ‘inner terror’ of lethal injection is cruel, law prof argues in bid to stop Gunches execution
Death by lethal injection looks like the condemned person just went to sleep. But looks can be deceiving. Anesthesiologists ...
Hickory Daily Record2d
Willow Sage Health & Wellness opens
Willow Sage Health & Wellness: IV Hydration/Injection Spa is now open in Taylorsville offering a variety of products and ...
Adelante Valle5d
After holiday pause, South Carolina begins scheduling executions again
South Carolina's Supreme Court set a Jan. 31 date for the state's next execution after allowing a pause for the Christmas ...
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
The American Journal of Managed Care6d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
FiercePharma6d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
ViewusGlobal on MSN8d
FDA Gives Green Light to Subcutaneous Opdivo – What This Means for Cancer Patients
FDA approves subcutaneous Opdivo, enhancing cancer treatment with similar efficacy to intravenous form and improved patient ...
Managed Healthcare Executive11d
FDA Approves Subcutaneous Opdivo to Treat Solid Tumors
Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in ...